Method for determining the efficiency of the treatment with interferon beta (IFN beta) in a subject with esclerosismultiple that includes determining at least one gene expression regulated by interferon(IRG) and / or its variant
A method is provided for determining the efficacy of interferon-beta (IFN-&bgr；) therapy in a subject with multiple sclerosis. One step of the method can include obtaining a biological sample from the subject. After obtaining the biological sample, the expression level of at least one interferon-regulated gene (IRG) and/or variant thereof can be determined. Increased or decreased expression of the at least one IRG and/or variant thereof as compared to a control may indicate that the subject will respond poorly to IFN-&bgr； therapy.METODO PARA DETERMINAR LA EFICIENCIA DEL TRATAMIENTO CON INTERFERON BETA (IFN-BETA) EN UN SUJETO CON ESCLEROSISMULTIPLE QUE COMPRENDE DETERMINAR LA EXPRESION DE AL MENOS UN GEN REGULADO POR INTERFERON (IRG) Y/O SU VARIANTE
